Glaukos ROA - Return on Assets 2014-2024 | GKOS

Glaukos return on assets for the quarter ending September 30, 2024 was -16.13.

  • Glaukos average return on assets for 2023 was -13.57, a 103.75% increase from 2022.
  • Glaukos average return on assets for 2022 was -6.66, a 18.29% increase from 2021.
  • Glaukos average return on assets for 2021 was -5.63, a 39.85% increase from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

Glaukos ROA - Return on Assets 2014-2024 | GKOS

  • Glaukos average return on assets for 2023 was -13.57, a 103.75% increase from 2022.
  • Glaukos average return on assets for 2022 was -6.66, a 18.29% increase from 2021.
  • Glaukos average return on assets for 2021 was -5.63, a 39.85% increase from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$212.6B
Intuitive Surgical (ISRG)$186.7B
Alcon (ALC)$45.7B
IQVIA Holdings (IQV)$39.5B
Edwards Lifesciences (EW)$38.8B
IDEXX Laboratories (IDXX)$35.5B
DexCom (DXCM)$26.9B
Waters (WAT)$22.9B
SONOVA HOLDING (SONVY)$22B
STERIS (STE)$21.3B
Hologic (HOLX)$18.4B
Fresenius Medical Care AG KGaA (FMS)$12.5B
Sysmex ADR (SSMXY)$12.4B
Globus Medical (GMED)$11.1B
Teleflex (TFX)$9.2B
Penumbra (PEN)$8.9B
Masimo (MASI)$8.6B
PROCEPT BioRobotics (PRCT)$5B
Integer Holdings (ITGR)$4.5B
Inari Medical (NARI)$3B
TransMedics (TMDX)$2.9B
Veracyte (VCYT)$2.9B
LivaNova (LIVN)$2.8B
Nihon Kohden (NHNKY)$2.5B
Elekta AB (EKTAY)$2.3B
Tandem Diabetes Care (TNDM)$2.2B
Integra LifeSciences Holdings (IART)$2B
RxSight (RXST)$1.9B
Alphatec Holdings (ATEC)$1.3B
Artivion (AORT)$1.2B